Topical Antifungals

Fungi are a harder target than bacteria because, like us, they are eukaryotes — their cells are built much like ours. The key exploitable difference is in the cell membrane: human membranes are stabilized by cholesterol, but fungal membranes depend on a different sterol, ergosterol. Nearly every antifungal works by attacking ergosterol — either blocking its synthesis or binding it directly — which cripples the fungal membrane while largely sparing human cells.

The classes divide by *where* they hit that pathway. Azoles (clotrimazole, miconazole, ketoconazole) inhibit the fungal enzyme 14-α-demethylase, blocking the conversion of lanosterol to ergosterol — they are fungistatic (they stop growth). Allylamines (terbinafine, naftifine) block an earlier enzyme, squalene epoxidase, causing toxic squalene to build up — terbinafine is fungicidal (it kills) and is first-line for nail and dermatophyte infections. Polyenes (nystatin) take a different route: they bind ergosterol directly, punching pores in the membrane — used for Candida (thrush, cutaneous).

The single most important clinical distinction in this class is topical versus systemic. Topical antifungals are remarkably safe — applied to intact skin, almost nothing is absorbed, so adverse effects are limited to local irritation (burning, itching, redness). They handle the common superficial infections: tinea (athlete’s foot, jock itch, ringworm), cutaneous candidiasis, tinea versicolor, and — via nystatin "swish and swallow" — oral thrush.

The oral/systemic azoles and terbinafine are a different story, because now the drug circulates through the whole body. Oral azoles (fluconazole, itraconazole, ketoconazole) are potent CYP450 inhibitors — they slow the metabolism of many other drugs (warfarin, statins, and more) — and, along with oral terbinafine, they are hepatotoxic, requiring liver-enzyme monitoring. Oral ketoconazole is the extreme case: it carries a boxed warning for serious hepatotoxicity and dangerous drug interactions (QT prolongation/torsades), so it is now last-line. The teaching point for the student: a topical antifungal is a low-stakes drug; the moment it becomes a pill, the interaction and liver conversations begin.

Topical antifungals are so safe that the main "adverse event" is really a behavioral one: treatment failure from stopping too early. Fungal skin infections feel better long before they are cured — the itch and redness fade within days, but the organism is still present in the deeper skin or nail. A patient who quits when symptoms improve gets a recurrence. So the counseling is explicit: complete the full course — often 2 weeks for jock itch, ~4 weeks for athlete’s foot/ringworm, and much longer for nails — even after the skin looks normal.

A few practical refinements help success. Apply to clean, dry skin, spread a thin layer slightly beyond the visible edge of the rash (dermatophytes advance at the border), and address the moisture that fungi love — dry between the toes, change socks, use breathable footwear. For oral thrush, teach the nystatin technique: swish the suspension around the mouth, hold it as long as possible, then swallow — and continue for ~48 hours after symptoms resolve to prevent relapse. These small habits convert a safe drug into an effective one.